Literature DB >> 23269104

Progressive multifocal leukoencephalopathy as the first manifestation of occult sarcoidosis: case report and review of the literature.

Matthew J Davis1, Adnan Khan, Walter Royal.   

Abstract

INTRODUCTION: Progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system, is caused by reactivation of the JC virus. This disease is typically seen in individuals with known immune suppression. It has also been associated with other inflammatory conditions, such as sarcoidosis. CASE REPORT: A 68-year-old woman without known immune suppression presented with mental status changes over several weeks. Brain biopsy and cerebrospinal fluid analysis led to the diagnosis of PML. On autopsy, she was found to have previously undiagnosed sarcoidosis.
CONCLUSIONS: To our knowledge, this is the first published case of PML as the first manifestation of sarcoidosis in the absence of inflammatory hematologic involvement.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23269104      PMCID: PMC5540643          DOI: 10.1097/NRL.0b013e31827c6c3d

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  10 in total

Review 1.  Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

Authors:  Igor J Koralnik
Journal:  Ann Neurol       Date:  2006-08       Impact factor: 10.422

2.  Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine.

Authors:  K Owczarczyk; R Hilker; A Brunn; M Hallek; A Rubbert
Journal:  Rheumatology (Oxford)       Date:  2007-03-27       Impact factor: 7.580

3.  Progressive multifocal leukoencephalopathy as first manifestation of sarcoidosis.

Authors:  Sylvie De Raedt; Patrick Lacor; Alex Michotte; Anja Flamez; Guy Ebinger
Journal:  Clin Neurol Neurosurg       Date:  2007-11-05       Impact factor: 1.876

4.  Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus.

Authors:  S Houston; N Roberts; L Mashinter
Journal:  Clin Infect Dis       Date:  2000-12-11       Impact factor: 9.079

5.  Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations.

Authors:  Nadera J Sweiss; Rafah Salloum; Seema Gandhi; Seema Ghandi; Maria-Luisa Alegre; Ray Sawaqed; Maria Badaracco; Kenneth Pursell; David Pitrak; Robert P Baughman; David R Moller; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

6.  The association of progressive multifocal leukoencephalopathy and sarcoidosis.

Authors:  M A Rosenbloom; D F Uphoff
Journal:  Chest       Date:  1983-03       Impact factor: 9.410

7.  Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

Authors:  W Royal; B Dupont; D McGuire; L Chang; K Goodkin; T Ernst; M J Post; D Fish; G Pailloux; H Poncelet; M Concha; L Apuzzo; E Singer
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

8.  Progressive multifocal leukoencephalopathy developed in incomplete Heerfordt syndrome, a rare manifestation of sarcoidosis, without steroid therapy responding to cidofovir.

Authors:  Takuya Yagi; Hidenori Hattori; Masayuki Ohira; Kazuo Nakamichi; Mutsuyo Takayama-Ito; Masayuki Saijo; Toshihiko Shimizu; Daisuke Ito; Kazushi Takahashi; Norihiro Suzuki
Journal:  Clin Neurol Neurosurg       Date:  2009-11-04       Impact factor: 1.876

9.  Progressive multifocal leukoencephalopathy developing in advanced pulmonal sarcoidosis.

Authors:  Hans-Ullrich Völker; Klaus Kraft; Eva Arnold; Silke Steinhoff; Georgios Kolios; Stephanie Sommer
Journal:  Clin Neurol Neurosurg       Date:  2007-06-29       Impact factor: 1.876

10.  Identification and characterization of mefloquine efficacy against JC virus in vitro.

Authors:  Margot Brickelmaier; Alexey Lugovskoy; Ramya Kartikeyan; Marta M Reviriego-Mendoza; Norm Allaire; Kenneth Simon; Richard J Frisque; Leonid Gorelik
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

  10 in total
  6 in total

1.  A prominent lactate peak as a potential key magnetic resonance spectroscopy (MRS) feature of progressive multifocal leukoencephalopathy (PML): Spectrum pattern observed in three patients.

Authors:  Duško Kozić; Mladen Bjelan; Jasmina Boban; Jelena Ostojić; Vesna Turkulov; Aleksandar Todorović; Slobodanka Lemajić-Komazec; Snežana Brkić
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

2.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

3.  Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab.

Authors:  Sina C Rosenkranz; Vivien Häußler; Manuela Kolster; Anne Willing; Jakob Matschke; Christoph Röcken; Klarissa Stürner; Frank Leypoldt; Eva Tolosa; Manuel A Friese
Journal:  Brain Commun       Date:  2021-12-16

4.  Progressive multifocal leukoencephalopathy as the first presentation of sarcoidosis.

Authors:  Maha Elbadri; Gordon Plant
Journal:  BMJ Case Rep       Date:  2020-08-26

5.  Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease.

Authors:  Paulette Scholten; Peter Kralt; Bram Jacobs
Journal:  BMJ Case Rep       Date:  2017-10-11

Review 6.  Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy.

Authors:  Huzaefah Syed; Christian Ascoli; Catharina Fm Linssen; Christen Vagts; Thomas Iden; Aamer Syed; Jordana Kron; Kelly Polly; David Perkins; Patricia W Finn; Richard Novak; Marjolein Drent; Robert Baughman; Nadera J Sweiss
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.